---
document_datetime: 2023-09-21 19:10:03
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/stalevo-epar-procedural-steps-taken-authorisation_en.pdf
document_name: stalevo-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5603132
conversion_datetime: 2025-12-20 15:56:03.293899
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## I BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Orion  Corporation  submitted  on  29  August  2002  an  application  for  Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Stalevo, through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  30  May  2002,  this  medicinal product  has  been  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No  (EEC)  2309/93  of 22 July 1993 as amended.

This  application  is  a  mixed  bibliographic  application  submitted  under  Article  10  1)  ii)  of  Directive 2001/83/EC whereby results of pharmacological and toxicological tests and clinical trials have been replaced  by  detailed  references  to  published  literature  demonstrating  that  some  of  the  constituents (levodopa/carbidopa)  have  a  well  established  medicinal  use,  with  recognised  efficacy  and  an acceptable level of safety.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur: Dr Pekka Kurki

## Scientific Advice

The  applicant  received  Scientific  Advice  from  the  CPMP  on  18  November  1999.  The  Scientific Advice pertained to parts III and IV of the dossier.

## Licensing status:

Stalevo has been given a Marketing Authorisation in the USA on 12 June 2003

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 23 September 2002.
- The Rapporteur's first Assessment Report was circulated to all CPMP  members  on 4 December 2002 (Annex 1). The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 2 December 2002
- During  the  meeting  on  21-23  January  2003  the  CPMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 23 January 2003.
- The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 19 March 2003
- The  response  Assessment  Report  on  the  applicant's  responses  to  the  List  of  Questions  was circulated to all CPMP members on 28 April 2003
- During the CPMP meeting on 20-22 May 2003 the List of outstanding issues was adopted and sent to the applicant on 22 May 2003.
- The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 4 June 2003
- The response Assessment Report on the applicant's responses to the List of Outstanding Issues was circulated to all CPMP members on 16 June 2003
- During the meeting on 24-26 June 2003 the CPMP, in the light of the overall data submitted and the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation on 26 June 2003.

Co-Rapporteur: Pr Christina Sampaio

<div style=\"page-break-after: always\"></div>

- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 17 October 2003.